WO2015152771A1 - Procédé de production d'un hydrogel médicinal - Google Patents
Procédé de production d'un hydrogel médicinal Download PDFInfo
- Publication number
- WO2015152771A1 WO2015152771A1 PCT/RU2015/000206 RU2015000206W WO2015152771A1 WO 2015152771 A1 WO2015152771 A1 WO 2015152771A1 RU 2015000206 W RU2015000206 W RU 2015000206W WO 2015152771 A1 WO2015152771 A1 WO 2015152771A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- medicine
- sodium
- dimethyl sulfoxide
- sodium alginate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 239000000017 hydrogel Substances 0.000 title claims description 13
- 230000001225 therapeutic effect Effects 0.000 title claims description 9
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 238000003756 stirring Methods 0.000 claims abstract description 44
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 36
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 35
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 35
- 239000000661 sodium alginate Substances 0.000 claims abstract description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 230000001954 sterilising effect Effects 0.000 claims abstract description 29
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000010199 sorbic acid Nutrition 0.000 claims abstract description 21
- 239000004334 sorbic acid Substances 0.000 claims abstract description 21
- 229940075582 sorbic acid Drugs 0.000 claims abstract description 21
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 13
- 229920000642 polymer Polymers 0.000 claims abstract description 13
- 239000011734 sodium Substances 0.000 claims abstract description 13
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 13
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims abstract description 12
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002684 aminocaproic acid Drugs 0.000 claims abstract description 10
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims abstract description 9
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims abstract description 9
- IKMNOGHPKNFPTK-UHFFFAOYSA-N 2-ethyl-6-methylpyridin-1-ium-3-ol;4-hydroxy-4-oxobutanoate Chemical compound OC(=O)CCC(O)=O.CCC1=NC(C)=CC=C1O IKMNOGHPKNFPTK-UHFFFAOYSA-N 0.000 claims abstract description 8
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims abstract description 8
- 229960001067 hydrocortisone acetate Drugs 0.000 claims abstract description 8
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960000282 metronidazole Drugs 0.000 claims abstract description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 7
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 7
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 7
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 7
- 235000010987 pectin Nutrition 0.000 claims abstract description 7
- 239000001814 pectin Substances 0.000 claims abstract description 7
- 229920001277 pectin Polymers 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 5
- 239000004202 carbamide Substances 0.000 claims abstract description 5
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims abstract description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 claims abstract description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 claims abstract description 4
- 241000241413 Propolis Species 0.000 claims abstract description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 4
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 4
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 4
- 150000004676 glycans Chemical class 0.000 claims abstract description 4
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 4
- 239000005017 polysaccharide Substances 0.000 claims abstract description 4
- 229940069949 propolis Drugs 0.000 claims abstract description 4
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 4
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 4
- 150000007513 acids Chemical class 0.000 claims abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 16
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 9
- 244000042664 Matricaria chamomilla Species 0.000 claims description 9
- 235000009108 Urtica dioica Nutrition 0.000 claims description 9
- 244000274883 Urtica dioica Species 0.000 claims description 7
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract 4
- 241000565379 Matricaria Species 0.000 abstract 3
- 235000017945 Matricaria Nutrition 0.000 abstract 3
- 241000219422 Urtica Species 0.000 abstract 3
- 244000078534 Vaccinium myrtillus Species 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 239000012153 distilled water Substances 0.000 description 28
- 239000000499 gel Substances 0.000 description 3
- -1 0.5% by mass Chemical compound 0.000 description 2
- 206010063057 Cystitis noninfective Diseases 0.000 description 2
- 241000218215 Urticaceae Species 0.000 description 2
- 201000003139 chronic cystitis Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the invention relates to the medical and pharmaceutical industries
- a known method of obtaining a therapeutic composition for intravesical therapy of chronic cystitis (Mirkin Y.B. Intravesical therapy of chronic cystitis // http://urotoday.ru/issue/6-2012/article/vnutripuzyrnaya-terapiya-khronicheskogo-tsistita.
- the method is based on the introduction in the polymer composition of sodium alginate and hyaluronic acid, drugs dioxidine and lidocaine.
- the disadvantages of this method include the fact that the therapeutic composition obtained in this way loses its viscosity characteristics during ⁇ -sterilization.
- the closest is a method of producing a therapeutic hydrogel, including the introduction of a drug into a polymer composition from a number of polysaccharides, gamma sterilization of 6-15 kGy (MA Korovina, “Development of a methodology and technology for creating therapeutic textile and hydrogel applications for targeted local drug delivery in radiation Therapy of Oncological Diseases (Theory and Practice) ”: Dis. ... Doctor of Technical Sciences: 05.19.02 / M.A. Korovin. - M, 2011. p.194-195).
- the polymer-thickener sodium alginate is introduced into distilled water and thoroughly mixed on a slow-moving mixer until it is completely dissolved and a homogeneous gel is obtained, and then a drug is added to the composition.
- the composition is thoroughly mixed in a kneading machine until a homogeneous mass is formed.
- the disadvantages of this method include the fact that the therapeutic composition obtained in this way also loses its viscosity characteristics during ⁇ -sterilization, and for a short time it retains biological stability before ⁇ -sterilization due to the possibility of high contamination.
- the objective of the invention is to provide a method for producing a biopolymer composition with a medicinal product, preserving more than 80% of its rheological, including viscosity properties during ⁇ -sterilization, increasing the time to maintain biological stability before ⁇ -sterilization, preventing the formation of microflora during the process an increase in the time of prolongation of the action of drugs.
- the concentration of the drug is proposed to choose from 0, 25 to 20 mass%, with the use of a drug selected from the series as a drug: ⁇ -aminocaproic acid or its mixture with lidocaine hydrochloride; Actovegin; a mixture of mexidol, dimethyl sulfoxide, hydrocortisone acetate and actovegin; propolis; nettles; chamomile or a mixture of nettle and chamomile; a mixture of nettle, chamomile and ⁇ -aminocaproic acid; metronidazole; dimethyl sulfoxide or a mixture of metronidazole and dimethyl sulfoxide; mexidol; sodium deoxyribonucleate or a mixture of sodium deoxyribonucleate and blueberries; a mixture of sodium dersoxyribonucleate and lidocaine hydrochloride; 5-fluorouracil; interleukin-1 beta; urea a mixture of dimethyl
- the proposed method eliminates the growth of microflora in the treatment hydrogel, avoiding large economic losses, allows delaying ⁇ -sterilization and does not allow the viscosity of the treatment hydrogel to drop during ⁇ -sterilization, provides the required period of prolongation of the drug.
- hyaluronic acid and 5 g of sodium alginate are poured into a 150 ml water tank, pour 94 ml of distilled water and mix thoroughly, leave for 60 minutes. Then they are mixed and 5% by mass of ⁇ -aminocaproic acid is introduced, mixed, after which sorbic acid at a concentration of 0.12% by mass is added to the composition with constant stirring until a homogeneous consistency is obtained. Pack and carry out gamma sterilization in a dose of bcGy.
- Example 10 1 g of hyaluronic acid and 5 g of sodium alginate are poured into a 150 ml water tank, pour 94 ml of distilled water and mix thoroughly, leave for 60 minutes. Then it is mixed and 0.3% by weight of Actovegin is introduced, mixed, After which sorbic acid is introduced into the composition with constant stirring at a concentration of 0.15% by mass, until a homogeneous consistency is obtained. Pack and carry out gamma sterilization in a dose of bcGy.
- the proposed method allows the manufacturer to produce high-quality products without unjustified economic losses, increase the processability by increasing the storage time and the possibility of reducing the biodegradability of the gel until sterilization, maintain the necessary viscosity characteristics of the gel while achieving its sterility during sterilization, allows you to create hydrogels with a wide range of drugs without changes in the technological equipment of the production cycle.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne les industries médicale et pharmaceutique. Le procédé consiste à introduire dans une composition polymère de la série des polysaccharides une préparation médicinale, une stérilisation 6-15 kGr. La nouveauté consiste en ce que l'on introduit dans la composition polymérique contenant la préparation médicinale, en remuant constamment, de l'acide sorbique ou ses sels hydrosolubles, ou de l'acide benzoïque ou ses sels hydrosolubles, ou un mélange de ces sels, ou un antibiotique dans une concentration de 0,05-1,00 % en masse jusqu'à obtenir une consistance homogène. En outre, on propose d'utiliser en tant que composition polymérique un mélange d'alginate de sodium et d'acide hyaluronique ou d'hyaluronate de sodium, avec un rapport de composants de 5:1 ou un mélange d'alginate de sodium et de pectine avec un rapport de composants de 6:1 ou de l'alginate de sodium gonflé. La concentration de la préparation médicinale peut être appliqué dans une fourchette de 0,25 à 20 % en masse, et on utilise en tant que préparation médicinale un produit choisi parmi: acide ε-aminocapronique ou son mélange avec de l'hydrochlorure de lidocaïne, Actovegin, mélange de Mexidol, diméthylsulfoxyde, acétate d'hydrocortisone et Actovegin, propolis, orties, camomille ou mélange d'orties et de camomille, mélange d'orties, de camomille et d'acide -aminocapronique, métronidazol, diméthylsulfoxyde ou mélange de métronidazol et de diméthylsulfoxyde, Mexidol, désoxyribonucléate de sodium ou mélange de désoxyribonucléate de sodium et de myrtille, mélange de désoxyribonucléate de sodium et d'hydrochlorure de lidocaïne, 5-fluorouracile, interleukine-1 bêta, urée, mélange de diméthylsulfoxyde et d'acétate d'hydrocortisone, dioxydine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014112519 | 2014-04-01 | ||
| RU2014112519/15A RU2563232C1 (ru) | 2014-04-01 | 2014-04-01 | Способ получения лечебного гидрогеля |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015152771A1 true WO2015152771A1 (fr) | 2015-10-08 |
Family
ID=54147742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/RU2015/000206 WO2015152771A1 (fr) | 2014-04-01 | 2015-03-31 | Procédé de production d'un hydrogel médicinal |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2563232C1 (fr) |
| WO (1) | WO2015152771A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111773259A (zh) * | 2020-08-07 | 2020-10-16 | 李伟泽 | 一种修复阴道黏膜损伤的植物药水凝胶制剂及其制备方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2653411C1 (ru) * | 2017-07-27 | 2018-05-08 | Общество с ограниченной ответственностью "КОЛЕТЕКС" | Способ получения лечебного гидрогеля |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| RU2209074C2 (ru) * | 2001-08-29 | 2003-07-27 | Общество с ограниченной ответственностью "Олимп" | Состав для лечения ожогов |
| US20060222616A1 (en) * | 2003-08-28 | 2006-10-05 | Tadashi Yoneda | Cosmetic composition comprising a and a lipopeptide |
| WO2006138518A1 (fr) * | 2005-06-17 | 2006-12-28 | Combinatorx, Incorporated | Polytherapie destinee au traitement de troubles immuno-inflammatoires |
| WO2010105634A1 (fr) * | 2009-03-17 | 2010-09-23 | United Technologies Ut Ag | Utilisation d'interleukine-1 bêta dans des compositions cosmétiques et ses procédés |
| RU2409371C1 (ru) * | 2009-08-17 | 2011-01-20 | Республиканское Унитарное производственное предприятие "Белмедпрепараты" | Обезболивающее, гемостатическое и ранозаживляющее средство |
| CA2609754C (fr) * | 2005-04-27 | 2012-01-10 | Shenzhen Phlora Biotechnology Limited | Compositions d'acide benzoique et de saccharides pour reguler et maintenir la flore bacterienne et l'acidite du vagin |
| RU2483755C1 (ru) * | 2012-04-26 | 2013-06-10 | Общество с ограниченной ответственностью "КОЛЕТЕКС" | Салфетка для лечения ран |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050191270A1 (en) * | 2004-02-27 | 2005-09-01 | Hydromer, Inc. | Anti-infectious hydrogel compositions |
-
2014
- 2014-04-01 RU RU2014112519/15A patent/RU2563232C1/ru not_active IP Right Cessation
-
2015
- 2015-03-31 WO PCT/RU2015/000206 patent/WO2015152771A1/fr active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| RU2209074C2 (ru) * | 2001-08-29 | 2003-07-27 | Общество с ограниченной ответственностью "Олимп" | Состав для лечения ожогов |
| US20060222616A1 (en) * | 2003-08-28 | 2006-10-05 | Tadashi Yoneda | Cosmetic composition comprising a and a lipopeptide |
| CA2609754C (fr) * | 2005-04-27 | 2012-01-10 | Shenzhen Phlora Biotechnology Limited | Compositions d'acide benzoique et de saccharides pour reguler et maintenir la flore bacterienne et l'acidite du vagin |
| WO2006138518A1 (fr) * | 2005-06-17 | 2006-12-28 | Combinatorx, Incorporated | Polytherapie destinee au traitement de troubles immuno-inflammatoires |
| WO2010105634A1 (fr) * | 2009-03-17 | 2010-09-23 | United Technologies Ut Ag | Utilisation d'interleukine-1 bêta dans des compositions cosmétiques et ses procédés |
| RU2409371C1 (ru) * | 2009-08-17 | 2011-01-20 | Республиканское Унитарное производственное предприятие "Белмедпрепараты" | Обезболивающее, гемостатическое и ранозаживляющее средство |
| RU2483755C1 (ru) * | 2012-04-26 | 2013-06-10 | Общество с ограниченной ответственностью "КОЛЕТЕКС" | Салфетка для лечения ран |
Non-Patent Citations (1)
| Title |
|---|
| KOROVINA M.A.: "«Razrabotka metodologii i tekhnologii sozdaniia lechebnykh tekstilnykh i gidrogelevykh applikatsii dlia napravlennoi mestnoi dostavki lekarstv pri luchevoi terapii onkologicheskikh zabolevanii (teoriia i praktika)»", AVTOREFERAT DISSERTATSII NA SOISKANIE UCHENOI STEPENI DOKTORA TEKHNICHESKIKH NAUK, 2011, pages 4 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111773259A (zh) * | 2020-08-07 | 2020-10-16 | 李伟泽 | 一种修复阴道黏膜损伤的植物药水凝胶制剂及其制备方法 |
| CN111773259B (zh) * | 2020-08-07 | 2021-08-31 | 李伟泽 | 一种修复阴道黏膜损伤的植物药水凝胶制剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2563232C1 (ru) | 2015-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lai et al. | Alginate‐based complex fibers with the Janus morphology for controlled release of co‐delivered drugs | |
| AU2013276844B2 (en) | Method of preparing a composition based on hyaluronic acid | |
| CN110536679B (zh) | 用于治疗乳腺炎的兽医用组合物和相关方法 | |
| CN103040728A (zh) | 一种壳聚糖妇用凝胶及其制备方法和医药应用 | |
| RU2563232C1 (ru) | Способ получения лечебного гидрогеля | |
| CN103254448A (zh) | 一种医用透明质酸钠凝胶及其制备方法 | |
| EP3316911B1 (fr) | Procédé de préparation d'une composition à base d'acide hyaluronique | |
| Jin et al. | Chitosan/PDLLA-PEG-PDLLA solution preparation by simple stirring and formation into a hydrogel at body temperature for whole wound healing | |
| CN101928355B (zh) | 一种氨基化海藻酸及其制备方法 | |
| Bosio et al. | Tailoring doxorubicin sustainable release from biopolymeric smart matrix using congo red as molecular helper | |
| Parfenyuk et al. | Silica hydrogel composites as a platform for soft drug formulations and cosmetic compositions | |
| EP2793910B1 (fr) | Procédé pour la fabrication de solution d'alginate partiellement réticulé | |
| Wu et al. | Stable thermosensitive in situ gel-forming systems based on the lyophilizate of chitosan/α, β-glycerophosphate salts | |
| US20160367606A1 (en) | Composition having hydrolyzed collagen and manuka honey | |
| CN103040729A (zh) | 一种祛痘痕壳聚糖凝胶及其制备方法和医药应用 | |
| CN107898757B (zh) | 一种载体药物及其制备方法 | |
| CN103446177B (zh) | 一种治疗妇科疾病的洗液及其制备方法 | |
| CN103463125B (zh) | 治疗妇科疾病的凝胶制剂及其制备方法 | |
| US20220347341A1 (en) | Hydrophobically-modified biopolymer materials | |
| RU2653411C1 (ru) | Способ получения лечебного гидрогеля | |
| CN104822707B (zh) | 基于结冷胶的流体胶的制备方法 | |
| MX2023014674A (es) | Metodos de fabricacion de formulaciones inyectables de liberacion sostenida. | |
| Hooda et al. | Chitosan nanoparticles: A marine polysaccharide for biomedical research | |
| TWI543777B (zh) | 溫敏型可注射式青光眼藥物載體凝膠及其製備方法 | |
| RU2535035C1 (ru) | Способ получения стерильной саможелирующейся альгинатной системы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15773373 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase | ||
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15773373 Country of ref document: EP Kind code of ref document: A1 |